Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis
Huzaifa Ul Haq Ansari, Shurjeel Uddin Qazi, Faiza Sajid, et al.
Endocrine Practice (2023) Vol. 30, Iss. 2, pp. 160-171
Closed Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study
Halis Kaan Aktürk, Fran Dong, Janet K. Snell‐Bergeon, et al.
Journal of Diabetes Science and Technology (2024)
Closed Access | Times Cited: 18
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
Areesha Moiz, Kristian B. Filion, Helia Toutounchi, et al.
Annals of Internal Medicine (2025) Vol. 178, Iss. 2, pp. 199-217
Closed Access | Times Cited: 5
The Physiology of Hunger
Alessio Fasano
New England Journal of Medicine (2025) Vol. 392, Iss. 4, pp. 372-381
Closed Access | Times Cited: 2
Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials
Gustavo de Oliveira Almeida, Thiago Nienkötter, Caroline Cristine Almeida Balieiro, et al.
American Journal of Cardiovascular Drugs (2024) Vol. 24, Iss. 4, pp. 509-521
Closed Access | Times Cited: 10
Experiences and overall impact reported by people living with obesity: results from a multinational study
Esther Artime, Swarna Khare, Sarah Zimner‐Rapuch, et al.
SAGE Open Medicine (2025) Vol. 13
Open Access | Times Cited: 1
New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions
Kyriazoula Chatzianagnostou, Melania Gaggini, Adrian Suman Florentin, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6218-6218
Open Access | Times Cited: 7
Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities
Riccardo Sarzani, Matteo Landolfo, Chiara Di Pentima, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 6
The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study
Mojca Jensterle, Simona Ferjan, Andrej Janež
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 5
Glucagon‐Like Peptide‐1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta‐Analysis of Randomized‐Controlled Trials
Alireza Hosseinpour, Aayushi Sood, Jahangir Kamalpour, et al.
Clinical Cardiology (2024) Vol. 47, Iss. 7
Open Access | Times Cited: 5
Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
Walter Masson, Martín Lobo, Juan Patricio Nogueira, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 5
Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care
Dimitrios Patoulias, Theocharis Koufakis, Ieva Ruža, et al.
Pragmatic and Observational Research (2024) Vol. Volume 15, pp. 139-149
Open Access | Times Cited: 5
The role of GLP‐1 receptor agonists in the management of obesity: risks and opportunities for the Australian health care system
Christopher Kanellis, Kyle Williams, Darcy Holt, et al.
The Medical Journal of Australia (2025)
Closed Access
Are glucagon-like peptide-1 receptor agonists anti-consummatory drugs?
Rodrigo B. Mansur, Joshua D. Di Vincenzo, Sebastian Badulescu, et al.
CNS Spectrums (2025), pp. 1-6
Closed Access
Obesity Management for Patients with Coronary Artery Disease and Heart Failure
Akheel A. Syed, Safwaan Adam, Christopher A. Miller, et al.
Heart Failure Clinics (2025) Vol. 21, Iss. 2, pp. 257-271
Closed Access
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists
Naim Alkhouri, Michael Charlton, Meagan Gray, et al.
Expert Opinion on Investigational Drugs (2025)
Closed Access
2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide
Melvin D.S. Wong, Pei‐Hsuan Lin, Wei‐Chen Lin, et al.
Journal of Medicinal Chemistry (2025)
Open Access
Effects of glucagon‐like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta‐analysis
Gianmaria Salvio, Alessandro Ciarloni, Nicola Ambo, et al.
Andrology (2025)
Open Access
Hypothesizing glucagon-like peptide 1 (GLP-1), agonists promote hypodopaminergia, resulting in heightened addictive reward-seeking and altered mood: Breaking the bubble and adding salt to a wound
Kenneth Blum, Catherine A. Dennen, Kai-Uwe Lewandrowski, et al.
Medical Hypotheses (2025), pp. 111612-111612
Closed Access
Liraglutide improves adipose tissue remodeling and mitochondrial dynamics in a visceral obesity model induced by a high-fat diet
Vanessa Touceda, Florencia Fontana Estevez, Leonardo Cacciagiú, et al.
Current Research in Pharmacology and Drug Discovery (2024) Vol. 6, pp. 100185-100185
Open Access | Times Cited: 4
The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease
Rong Ren, Yanxi Pei, Lufei Kong, et al.
Journal of Diabetes and its Complications (2024) Vol. 39, Iss. 2, pp. 108932-108932
Closed Access | Times Cited: 2
Phenylpiracetam: molecular mechanisms of effects in obesity
О. А. Громова, I. Yu. Torshin, Л. Б. Лазебник
Meditsinskiy sovet = Medical Council (2024), Iss. 6, pp. 124-131
Open Access | Times Cited: 1
Chemoreactomic study of fonturacetam effects: molecular mechanisms of influence on adipose tissue metabolism
О. А. Громова, I. Yu. Torshin
FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology (2024) Vol. 17, Iss. 2, pp. 172-181
Open Access | Times Cited: 1
The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression
Moein Ala, Mohammadreza Moheb Aleaba
Journal of Endocrinological Investigation (2024)
Closed Access | Times Cited: 1
The Influence of GLP1 on Body Weight and Glycemic Management in Patients with Diabetes—A Scientometric Investigation and Visualization Study
Ileana Pantea, Angela Repanovici, Oana Andreescu
Medicina (2024) Vol. 60, Iss. 11, pp. 1761-1761
Open Access | Times Cited: 1
Treatment strategies to reduce cardiovascular risk in persons with chronic kidney disease and Type 2 diabetes
Faı̈ez Zannad, Darren K. McGuire, Alberto Ortíz
Journal of Internal Medicine (2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top